Загрузка видео...

Не удалось загрузить видео

На главную

In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Read the full TARGET-FIRST trial results in the Original Article “Early Discontinuation of Aspirin...

NEJM's profile picture

NEJM

1,018,874 subscribers

32,419 просмотров • 8 месяцев назад •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:
1:06

In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results and Research Summary:

NEJM

12,312 просмотров • 4 месяцев назад

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib
1:28

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results and Research Summary: #Cardiology #AFib

NEJM

15,621 просмотров • 4 месяцев назад

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:
0:58

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results and Research Summary:

NEJM

12,257 просмотров • 5 месяцев назад

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:
1:28

NEJM Editorial Fellow Minali Nigam, MD, shares the key results of the ORIENTAL-MeVO trial, which investigated whether endovascular thrombectomy for acute ischemic stroke improves functional outcomes in patients with medium-vessel occlusion and moderate-to-severe deficits. Read the full trial results:

NEJM

16,994 просмотров • 21 дней назад

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.
1:12

Everything we have learned so far about the revascularization of non-culprit lesions in patients with acute myocardial infarction and multivessel disease... in 1 minute.

Davide Capodanno

28,505 просмотров • 2 лет назад

Catheter-Directed PE Treatment: Does it Deliver? NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains a trial recently published in NEJM that compared catheter-directed thrombolysis to anticoagulation alone for acute, intermediate-risk pulmonary embolism. Read the key results and comment from Michael E. Billington, MD: Visit to see What Matters Most This Week, including: 🫀 New ACC/AHA Guideline on Lipid Management and ASCVD Prevention 💊 Chronic Beta-Blocker Use in Low-Risk Patients after MI: Time to Re-Evaluate 🧠 Reducing the Risk of Recurrent Stroke in Patients with Left Ventricular Dysfunction 🎯 What's the Ideal LDL Target for Patients with Cardiovascular Disease?
1:07

Catheter-Directed PE Treatment: Does it Deliver? NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD (Raja-Elie Abdulnour), explains a trial recently published in NEJM that compared catheter-directed thrombolysis to anticoagulation alone for acute, intermediate-risk pulmonary embolism. Read the key results and comment from Michael E. Billington, MD: Visit to see What Matters Most This Week, including: 🫀 New ACC/AHA Guideline on Lipid Management and ASCVD Prevention 💊 Chronic Beta-Blocker Use in Low-Risk Patients after MI: Time to Re-Evaluate 🧠 Reducing the Risk of Recurrent Stroke in Patients with Left Ventricular Dysfunction 🎯 What's the Ideal LDL Target for Patients with Cardiovascular Disease?

NEJM

12,682 просмотров • 4 месяцев назад

"Taking An Aspirin Everyday To Prevent A Heart Attack Is Wrong, Dangerous & Can Be Deadly." Dr Jack Wolfson, Cardiologist "A Daily Aspirin Is A Lie That's Been Fed To Us For Over 50 Years." "Aspirin Does Not Protect You Or Fix Your Damaged Arteries...It Just Makes You Bleed." Almost 30 million Americans take aspirin for primary or secondary prevention of cardiovascular disease (CVD) or colorectal cancer (CRC). For decades, low dose Aspirin has been prescribed to patients as primary prevention for patients at risk for CVD, but has now been withdrawn as a line of treatment or prevention. The most recent recommendations from the US Preventive Services Task Force (USPSTF) have abandoned the routine call for daily aspirin use because of the harms that daily low dose aspirin causes. Research From The ARRIVE, ASPREE & ASCEND Peer Reviewed Studies, Confirms That Daily Aspirin, Even Low Dose 'Baby Aspirin,' Is Harmful & Causes Major Bleeding: More than 46,000 adults were studied for multiple years on low dose enteric coated 100 mg aspirin & found significant major bleeding while also finding no benefit for cardiovascular disease. The causal factor of the increased risk of bleeding is aspirin inhibits platelet activity as a COX-1 inhibitor, which damages the protective layer of gastrointestinal mucosa, intracranial brain tissue & micro bleeding anemia. 1⃣ Increased risk of major bleeding: This includes gastrointestinal (GI) bleeding (e.g., ulcers, bleeding in the stomach or intestines) & intracranial hemorrhage (bleeding in the brain), which can be severe & life-threatening. 2⃣ Hemorrhagic stroke: Aspirin increases the risk of hemorrhagic strokes, where a blood vessel bursts in the brain. Bleeding events were 38% higher among participants who were taking aspirin daily, regardless of their gender, age, or cardiovascular risk. 3⃣ Anemia: The ASPREE trial, showed 20% increase in Anemia, characterized by low red blood cell counts & symptoms like fatigue & weakness. Slow micro bleeding anemia as low Hemoglobin iron & Ferritin levels plummeting to less than 45 mcg/L. 4⃣ Gastrointestinal damage: Aspirin, even at low doses, causes damage to the lining of the stomach & intestines, leading to erosions, ulcers & bleeding. Research participant data showed 60% had major GI bleeds as a result of a daily low dose aspirin. 👇ASCEND Aspirin Bleeding Risk Study👇 👇Daily Low Dose Aspirin Causes Anemia👇 👇ASPREE Low Dose Aspirin Causes GI Bleeding👇 Speaker: Dr Jack Wolfson, MD
2:09

"Taking An Aspirin Everyday To Prevent A Heart Attack Is Wrong, Dangerous & Can Be Deadly." Dr Jack Wolfson, Cardiologist "A Daily Aspirin Is A Lie That's Been Fed To Us For Over 50 Years." "Aspirin Does Not Protect You Or Fix Your Damaged Arteries...It Just Makes You Bleed." Almost 30 million Americans take aspirin for primary or secondary prevention of cardiovascular disease (CVD) or colorectal cancer (CRC). For decades, low dose Aspirin has been prescribed to patients as primary prevention for patients at risk for CVD, but has now been withdrawn as a line of treatment or prevention. The most recent recommendations from the US Preventive Services Task Force (USPSTF) have abandoned the routine call for daily aspirin use because of the harms that daily low dose aspirin causes. Research From The ARRIVE, ASPREE & ASCEND Peer Reviewed Studies, Confirms That Daily Aspirin, Even Low Dose 'Baby Aspirin,' Is Harmful & Causes Major Bleeding: More than 46,000 adults were studied for multiple years on low dose enteric coated 100 mg aspirin & found significant major bleeding while also finding no benefit for cardiovascular disease. The causal factor of the increased risk of bleeding is aspirin inhibits platelet activity as a COX-1 inhibitor, which damages the protective layer of gastrointestinal mucosa, intracranial brain tissue & micro bleeding anemia. 1⃣ Increased risk of major bleeding: This includes gastrointestinal (GI) bleeding (e.g., ulcers, bleeding in the stomach or intestines) & intracranial hemorrhage (bleeding in the brain), which can be severe & life-threatening. 2⃣ Hemorrhagic stroke: Aspirin increases the risk of hemorrhagic strokes, where a blood vessel bursts in the brain. Bleeding events were 38% higher among participants who were taking aspirin daily, regardless of their gender, age, or cardiovascular risk. 3⃣ Anemia: The ASPREE trial, showed 20% increase in Anemia, characterized by low red blood cell counts & symptoms like fatigue & weakness. Slow micro bleeding anemia as low Hemoglobin iron & Ferritin levels plummeting to less than 45 mcg/L. 4⃣ Gastrointestinal damage: Aspirin, even at low doses, causes damage to the lining of the stomach & intestines, leading to erosions, ulcers & bleeding. Research participant data showed 60% had major GI bleeds as a result of a daily low dose aspirin. 👇ASCEND Aspirin Bleeding Risk Study👇 👇Daily Low Dose Aspirin Causes Anemia👇 👇ASPREE Low Dose Aspirin Causes GI Bleeding👇 Speaker: Dr Jack Wolfson, MD

Valerie Anne Smith

209,973 просмотров • 1 год назад

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:
1:18

Our latest video in our partnership with Dr. Glaucomflecken summarizes the results of a trial that evaluated whether management of shock without early arterial catheterization is noninferior to the practice of early catheter insertion with regard to death from any cause at day 28. Read the full results for free:

NEJM

47,843 просмотров • 7 месяцев назад

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:
1:29

Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than placebo. Read the full results of the CORE-TIMI 72a and CORE2-TIMI 72b trials:

NEJM

13,328 просмотров • 6 месяцев назад

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full trial results and Research Summary:
1:04

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full trial results and Research Summary:

NEJM

25,324 просмотров • 6 месяцев назад

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR
1:46

In a trial of patients with bifurcation lesions, main branch stenting and POT, ending the procedure with no further intervention was noninferior to POT-side-POT or kissing balloon inflation for myocardial injury or infarction, and less likely required a second stent. #EuroPCR

PCRonline 🫀

31,019 просмотров • 3 лет назад

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:
1:20

In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results of the CREST-2 trials and Research Summary:

NEJM

18,745 просмотров • 7 месяцев назад

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:
1:20

What is the appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation? View the full results of the AQUATIC trial:

NEJM

16,263 просмотров • 9 месяцев назад

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:
1:27

Our latest video in our partnership with Dr. Glaucomflecken summarizes the POTCAST trial, which assessed a strategy of actively increasing plasma potassium levels to the high-normal range in patients at high risk for ventricular arrhythmias. Read the full study for free:

NEJM

89,819 просмотров • 6 месяцев назад

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:
1:46

In the latest video in our partnership with Dr. Glaucomflecken, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free:

NEJM

144,797 просмотров • 1 год назад

A population-based study in Ontario, Canada, examined outcomes for more than 28,000 individuals treated for a nonfatal #opioidoverdose and discharged from the #emergency department. Within 1 year, more than 1 in 5 had a repeat overdose, nearly 9% died, with nearly two-thirds of deaths resulting from another opioid overdose. The 1-year #mortality rate was higher among those with a prior overdose in the preceding 5 years. These findings indicate that the post-discharge period is a time of acute, sustained risk and highlight the importance of low-barrier interventions such as opioid agonist therapy, take-home #naloxone, and rapid follow-up for #survivors. 📖 Read the full article to learn more:
1:59

A population-based study in Ontario, Canada, examined outcomes for more than 28,000 individuals treated for a nonfatal #opioidoverdose and discharged from the #emergency department. Within 1 year, more than 1 in 5 had a repeat overdose, nearly 9% died, with nearly two-thirds of deaths resulting from another opioid overdose. The 1-year #mortality rate was higher among those with a prior overdose in the preceding 5 years. These findings indicate that the post-discharge period is a time of acute, sustained risk and highlight the importance of low-barrier interventions such as opioid agonist therapy, take-home #naloxone, and rapid follow-up for #survivors. 📖 Read the full article to learn more:

JAMA

16,085 просмотров • 12 дней назад

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:
1:14

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events. Full phase 3 LITESPARK-022 trial results and Research Summary:

NEJM

12,637 просмотров • 1 месяц назад

Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial. #ACC26 American College of Cardiology 🎥 Watch the video and read the full article:
1:23

Among patients with #diabetes but without known significant atherosclerosis, intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo in the VESALIUS-CV trial. #ACC26 American College of Cardiology 🎥 Watch the video and read the full article:

JAMA

14,124 просмотров • 4 месяцев назад

Well, it depends... who do you want to yell at you? Cardiology or Nephrology? Our latest video in partnership with Dr. Glaucomflecken summarizes the ARISE FLUIDS trial that examined whether hemodynamic resuscitation with early vasopressors versus more liberal fluids could affect outcomes in patients with septic shock. Read the full study for free: #emergencymedicine
0:58

Well, it depends... who do you want to yell at you? Cardiology or Nephrology? Our latest video in partnership with Dr. Glaucomflecken summarizes the ARISE FLUIDS trial that examined whether hemodynamic resuscitation with early vasopressors versus more liberal fluids could affect outcomes in patients with septic shock. Read the full study for free: #emergencymedicine

NEJM

37,449 просмотров • 2 дней назад

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:
1:32

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:

NEJM

15,827 просмотров • 1 месяц назад